Page 2 - Uro_Onco_booklet

Contents
Part 1: Management of Men with Castration-Naïve mPC . . . . . . . . . . . . . p3
Part 2: Management of Men with Castration-Resistant mPC (mCRPC) . . p5
Part 3: Value and Use of Predictive Markers in mCRPC . . . . . . . . . . . . . . p7
Part 4: Sequencing Treatment in mCRPC . . . . . . . . . . . . . . . . . . . . . . . . . p8
Part 5: Management of Men with Oligometastasis . . . . . . . . . . . . . . . . . p9
Part 6: Staging and Monitoring of mCRPC Treatment . . . . . . . . . . . . . . . p10
Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . p11

Objectives
• The management paradigm for metastatic prostate cancer (mPC) is
evolving in recent years.
• An expert panel was organised locally to establish consensus statements,
hoping to facilitate local management strategies for patients with mPC.
• The statements were primarily derived from recent clinical evidence, with
the consideration of local clinical experience and practicability.

Areas of the Consensus Statements
The consensus statements are divided into 6 areas in total:
i. Management of men with castration-naïve mPC
ii. Management of men with metastatic castration-resistant
prostate cancer (mCRPC)
iii. Value and use of predictive markers in mCRPC
iv. Sequencing treatment in mCRPC
v. Management of men with oligometastasis
vi. Staging and monitoring of mCRPC treatment

2